作者：
Alejo,Rodriguez-Vida [1]
;
Pablo,Maroto [2]
;
Albert,Font [3]
;
Cristina,Martin [2]
;
Begoña,Mellado [4]
;
Alex,Corbera [5]
;
Mayra,Orrillo [6]
;
Oscar,Reig [7]
;
Rosa,Querol [1]
;
Alejandro,Rios-Hoyo [1]
;
Laia,Cano [4]
;
Judith,Alonso [5]
;
Gemma,Martinez [6]
;
Susana,Galtes [7]
;
Alvaro,Taus [8]
;
Maria,Martinez-Garcia [1]
;
Nuria,Juanpere [9]
;
Oscar,Juan [9]
;
Joaquim,Bellmunt [9]
作者单位：
Medical Oncology Department, Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain.
[1]
Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
[2]
Medical Oncology Department, Catalan Institute of Oncology - Badalona, B-ARGO Group, IGTP, Barcelona, Spain.
[3]
Medical Oncology Department, Hospital Clínic, Barcelona, Spain.
[4]
Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
[5]
Uro-Oncology Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain.
[6]
Department of Medicine, University of Barcelona, Barcelona, Spain.
[7]
Medical Oncology Department, Hospital de Mataró, Barcelona, Spain.
[8]
Clinical Trials Unit, Hospital del Mar, Barcelona, Spain.
[9]
Pathology Department, Hospital del Mar, Barcelona, Spain.
[10]
Pivotal SLU Clinical Research Organization, Madrid, Spain.
[11]
Medical Oncology Department, Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain. joaquim_bellmunt@dfci.harvard.edu.
[12]
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. joaquim_bellmunt@dfci.harvard.edu.
[13]
DOI
10.1038/s41416-022-01991-4
PMID
36289372
发布时间
2023-10-27
换一批
换一批
